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[1] knockout mice [4] . Changes in renal ET-1 expression/ first offered the most consistent unifying hypothesis on synthesis correlate with progressive renal damage in the progressive nature of renal disease, suggesting that this model [5] [6] [7] . Increased renal synthesis of ET-1 the surviving nephrons initially spared by the disease was also found in rats with passive Heymann nephritis activate common haemodynamic responses which, (PHN ), an immune model of glomerular disease resemwhile serving to maintain glomerular filtration, cause bling human membranous nephropathy [8, 9] . Other structural injury in a self-perpetuating cycle [1]. More studies have found an up-regulation of renal ET-1 and recently, studies have established that an excessive and ET B receptor gene expression in NZB/WF1 mice that sustained protein traffic through the nephron, as a have an immunological disease reminiscent of human consequence of high glomerular capillary pressure, lupus [10] . Glomerular ET-1 and ET B receptor invariably is associated with the progress of the disease mRNAs were higher than normal within few days after and exerts intrinsic renal toxicity per se [2] . The puromycin aminonucleoside injection and normalized proteins filtered in excessive amounts accumulate in when rats were no longer nephrotic [11] . Also in the lumen of the proximal tubule and are actively experimental diabetes, mRNA for ET-1 is overexreabsorbed by the tubular epithelium, causing an pressed in the kidney in the face of unchanged ET A intracellular congestion that, in the long term, pro-and ET B receptors [12] . motes tubulointerstitial injury and renal scarring.
The most elegant and direct evidence that ET-1 Excessive protein reabsorption would induce func-plays a role in progressive renal damage derives from tional alterations of tubular cells that overexpress studies using transgenic animals. Mice overexpressing inflammatory and vasoactive molecules mainly secreted the human ET-1 promoter generate more ET-1 in their towards the interstitium where they trigger an inter-kidney and develop renal lesions despite no increase stitial inflammatory reaction, fibroblast proliferation in systemic blood pressure [13] . Furthermore, rats and extracellular matrix deposition, key features of transgenic for the human ET-2 gene are normotensive renal scarring. Overload of proximal tubular cells in and develop renal lesions reminiscent of those seen in culture with excess proteins induces a dose-dependent rats with remnant kidney [14] . Several lines of evidence increase in the synthesis and release of endothelin-1 using ET receptor antagonists definitely support the ( ET-1) [3], a peptide with vasoconstrictor and prolif-possible role of ET-1 in renal diseases and provide eration properties, which, by virtue of its chemotactic important indications for future clinical use of these activity, attracts blood monocytes and stimulates them compounds to slow or even halt disease progression. to produce proinflammatory cytokines, which would Thus, in the rat remnant kidney model, a specific further amplify the interstitial inflammatory reaction. antagonist for the ET A receptor [15] ameliorated renal Increased renal gene expression and synthesis of function and protected against glomerular and tubulo-ET-1 have been reported in proteinuric progressive interstitial structural injury. Similar results have been nephropathies from either immune or non-immune achieved recently using an ET A and a non-selective origin (Table 1 was also evident in mice with experimental lupus [18] . The same molecule was effective in receptor antagonist to patients with chronic renal failure reduced blood pressure and renal vascular resistpreventing the development of renal lesions and attenuating the increase in serum creatinine in rats with ance [24] . A very recent study has shown that patients with chronic glomerulopathy whose urinary protein streptozotocin-induced experimental diabetes treated at the moment of induction of the disease [19] . More excretion was >2 g, had an increased expression of ET-1 and ET B receptor in their kidney, as previously recently, data became available to indicate that an unselective ET A /ET B receptor antagonist, when chron-observed in rats with progressive renal disease [25] . Pre-clinical studies consistently have demonstrated ically administered to diabetic animals with overt proteinuria, was as effective as an angiotensin-converting a role for ET-1 in renal disease progression and a considerable renoprotection of endothelin receptor antenzyme inhibitor (ACEI ) on blood pressure and protein excretion [20] .
agonists. Clinical studies are now mandatory to assess the applicability of such animal results to human. Pharmacological tools, which effectively reduce proteinuria, such as the ACEIs, also limit renal damage and prevent renal function deterioration. These effects References invariably were associated with reduction of the exaggerated renal synthesis of ET-1. A recent study [21] 
